Purpose

This is a phase IV post-marketing study for MagnetOs Putty and MagnetOs Easypack Putty. MagnetOs is a synthetic bone graft extender product that is routinely used by surgeon as treatment for hindfoot and ankle disorders. In this study, MagnetOs Putty and MagnetOs Easypack Putty will be use according to the latest Instructions For Use, standalone in the foot and ankle.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 75 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Criteria

Inclusion:

1. Patient is able to read/be read, understand, and provide written informed consent
and has signed the IRB approved informed consent.

2. Male or female patient ≥ 18 (considered skeletally mature) up to and including 75
years old

3. Patients requiring one of the following hindfoot fusion procedures, using surgical
technique, necessitating rigid hardware fixation and supplemental bone graft/
substitute: ankle fusion (tibiotalar) subtalar fusion (talocalcaneal),
calcaneocuboid fusion, talonavicular fusion, OR double fusion (any combination of
any two of the following: subtalar, talonavicular and calcaneocuboid joints).

4. Hardware parameters - rigid fixation using screws, plates, staples, nails or a
combination.

Exclusion:

1. Expected to need secondary intervention within one year following surgery.

2. Had prior fusion or attempted fusion of the joints to be fused.

3. Patient is not ambulatory.

4. Surgical technique where bone graft is not expected to be used.

5. Conditions at the surgeon's discretion in which general bone grafting is not
advisable.

6. Radiographic evidence of fractures or pathologies around the fusion that could
negatively impact the fusion process (e.g., growth plate fracture around the fusion
or bone cysts).

7. Significant vascular impairment proximal to the graft site.

8. Acute and/or chronic infections in the operated area (soft tissue infections;
bacterial bone diseases; osteomyelitis)

9. Pre-existing sensory impairment (e.g. diabetes, Charcot). Diabetics patients with
HbA1c greater than 7.0 OR that were not sensitive to the 5.07 monofilament will be
excluded.

10. Metabolic disorders know to adversely affect the skeleton (e.g., renal
osteodystrophy or hypercalcemia).

11. If intraoperative soft tissue coverage is not planned or possible.

12. Receiving treatment with medication interfering with calcium metabolism (chronic use
of glucocorticoid and use high dose NSAIDs 800 mg TID for > the first 6 weeks
post-op).

13. Has benign or malignant tumor at the surgical site.

14. Has history or presence of active malignancy (non-invasive skin cancer is allowed).

15. Has known substance abuse, psychiatric disorder, or a condition which, in the
opinion of the investigator, may influence the healing or ability to comply with
protocol requirements (e.g. prisoners, physically or mentally compromised, etc.).

16. Is involved in active litigation relating to his/her foot and ankle condition.

17. Participation in an investigational study within 30 days prior to surgery for study
devices.

18. Patient with body mass index (BMI) > 50.

19. Patient cannot comply with all post-operative evaluation and visits .

20. Any pre-existing condition that the surgeon determines could interfere with the
patient's ability to perform objective functional measurements.

21. Women who are or intend to become pregnant within the next 12 months.

Study Design

Phase
N/A
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
Single (Participant)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
MagnetOs
Interventions - Procedure: Instrumented hindfoot or ankle fusion - Device: MagnetOs Putty or MagnetOs Easypack Putty
  • Device: MagnetOs
    MagnetOs will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.
Active Comparator
Autograft
Interventions - Procedure: Instrumented hindfoot or ankle fusion - Device: Autograft
  • Other: Autograft
    In this study, the comparator is autograft and will be used at a volume of approximately 1-5 cc's for the TN, CC and ST joints, and up to 10 cc's for the tibiotalar joint.

Recruiting Locations

Steadman Philippon Research Institute
Vail, Colorado 81657
Contact:
Jonathon Backus, MD
jbackus@thesteadmanclinic.com

Hughston Foundation Inc
Columbus, Georgia 31909
Contact:
Collier Watson, MD
b.collier.watson@gmail.com

OrthoCarolina Research Institute, Inc
Charlotte, North Carolina 28207
Contact:
Samual Ford, MD
samuel.ford@orthocarolina.com

Reconstructive Orthopaedic Associates II dba Rothman Orthopaedic Institute
Philadelphia, Pennsylvania 19107
Contact:
Selene Parekh, MD
selene.parekh@rothmanortho.com

Integrity Orthopedics and Sports Medicine
Chattanooga, Tennessee 37404
Contact:
Principal Investigator, Jesse Doty, MD

Centers for Advanced Orthopaedics
Falls Church, Virginia 22042
Contact:
Steve Neufeld, MD
sneufeld@cfaortho.com

More Details

Status
Recruiting
Sponsor
Kuros Biosurgery AG

Study Contact

Cesar Silva, MD
9702156793
cesar.silva@kurosbio.com

Detailed Description

In this study, following a screening period of a maximum of 45 days, approximately 126 patients will receive either MagnetOs Putty/Easypack Putty or autograft in conjunction with rigid hardware (arthrodesis) to treat hindfoot and ankle disorders. They will be randomized (1:1) into one of two treatment groups: standard rigid fixation with MagnetOs Putty/Easypack Putty or local autograft from the calcaneus, distal tibia, or proximal tibia. They will be followed up at discharge at weeks 2, 6, 12, 24 and 52 post-surgery. The primary endpoint will be analyzed at 24 weeks post-op using CT-scan, and patients will continue follow-up for safety and efficacy for one year post operatively. In this study, MagnetOs will be applied according to the IFU (Putty) approved in the US, Europe, Middle- East and Australia and Easypack Putty (approved in the US). The surgical procedures studied in this clinical trial will include rigid hardware fixation and supplemental bone graft/substitute in the following procedures: ankle fusion (tibiotalar), subtalar fusion (talocalcaneal), calcaneocuboid fusion, talonavicular fusion, OR double fusion (any combination of any two of the following: subtalar, talonavicular and calcaneocuboid joints. These procedures will be left to the investigator's discretion. Radiographs images will be taken at screening, weeks 6, 12, 24 and 52; CT-scans will be taken at weeks 24 and 52 post-op If the patient has a secondary surgical intervention (procedure that adjusts or in any way modifies or removes part of the original implant configuration) at any time after the 6 month visit, the next CT scan will not be necessary. Starting at week 12, all XR images will be weight bearing.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.